Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies

Daniel Re (), Barbara Seitz-Polski, Vesna Brglez, Michel Carles, Daisy Graça, Sylvia Benzaken, Stéphane Liguori, Khaled Zahreddine, Margaux Delforge, Béatrice Bailly-Maitre, Benjamin Verrière, Emmanuel Chamorey and Jérôme Barrière ()
Additional contact information
Daniel Re: Centre Hospitalier
Barbara Seitz-Polski: Université Côte d’Azur
Vesna Brglez: Université Côte d’Azur
Michel Carles: Centre Hospitalier Universitaire de Nice (CHU)
Daisy Graça: Université Côte d’Azur
Sylvia Benzaken: Université Côte d’Azur
Stéphane Liguori: Centre Hospitalier
Khaled Zahreddine: Centre Hospitalier
Margaux Delforge: Centre Hospitalier
Béatrice Bailly-Maitre: INSERM, C3M, Université Côte d’Azur
Benjamin Verrière: Centre Hospitalier
Emmanuel Chamorey: Centre Antoine Lacassagne
Jérôme Barrière: Polyclinique Saint-Jean

Nature Communications, 2022, vol. 13, issue 1, 1-9

Abstract: Abstract Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia (n = 13), B cell non-Hodgkin lymphoma (n = 14), and multiple myeloma (n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-28578-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28578-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-28578-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().